CompletedNCT06408324
Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Research Consortium on ITP
- Principal Investigator
- Maria L. Lozano, M.D.Hematology and Medical Oncology Dept. Hospital General Universitario José María Morales Meseguer
- Enrollment
- 275 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (17)
- Hôpital Universitaire Henri Mondor, Créteil, France
- CHU Dijon - Hôpital François Mitterrand Médecine 1 - Etudes Cliniques, Dijon, France
- CHU Toulouse - Hôtel-Dieu Saint-Jacques, Toulouse, France
- Careggi Hospital, Florence, Italy
- Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy
- San Bortolo Hospital, Vicenza, Vicenza, Italy
- Bergen Hospital, Bergen, Norway
- Oslo Hospital, Oslo, Norway
- Østfold Hospital, Oslo, Norway
- Hospital del Mar, Barcelona, Barcelona, Spain
- Hospital General Universitario de Burgos, Burgos, Spain
- Hospital Morales Meseguer, Murcia, Spain
- Basel university hospital, Basel, Switzerland
- Bern university hospital, Bern, Switzerland
- Lausanne University hospital, Lausanne, Switzerland
- +2 more locations on ClinicalTrials.gov
Collaborators
Fondazione Progetto Ematologia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06408324 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07421167A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals